Spyre Therapeutics is a clinical-stage biotech company developing antibody-based medicines for inflammatory bowel disease and rheumatic conditions. Its pipeline includes several monoclonal antibodies targeting specific immune pathways—such as SPY001 (in phase 2 for IBD), SPY002 and SPY072 (targeting TL1A), and SPY003 (targeting IL-23)—as well as combination therapies designed to address multiple disease mechanisms simultaneously. The company was incorporated in 2013 and is headquartered in Waltham, Massachusetts.

entry readiness 45 · WEAK SETUP · exit proximity 15

Value area 60.49–95.79 · 28% of 120d volume overhead · moderate overhead